The excellent antitumor effect of apatinib alone as second-line therapy in a patient with sorafenib-refractory hepatocellular carcinoma: A case report

We report an advanced HCC patient with many lung metastases who failed sorafenib treatment. Diagnoses: Sorafenib refractory HCC patient with a large number of lung metastases. Interventions: The apatinib alone was used as second line therapy. Outcomes: The patient achieved partial response (PR) soon after the treatment, which was maintained for approximately 1 year. During the entire process, the lung metastases continued to diminish. Finally, only a few lesions remained Lessons: Apatinib alone may be a good second-line therapy for advanced HCC patients who are refractory to sorafenib. However, further investigation in future prospective clinical studies is warranted.
Source: Medicine - Category: Internal Medicine Tags: Research Article: Clinical Case Report Source Type: research